Skip to main content
NCBI home page
British Heart Journal logoLink to British Heart Journal
. 1993 Aug;70(2):141–143. doi: 10.1136/hrt.70.2.141

Tumour necrosis factor alpha in severe congestive cardiac failure.

D P Dutka 1, J S Elborn 1, F Delamere 1, D J Shale 1, G K Morris 1
PMCID: PMC1025274  PMID: 8038024

Abstract

OBJECTIVE--To examine the concentration of circulating tumour necrosis factor alpha (TNF alpha) in patients with severe congestive heart failure (New York Heart Association class IV) during one year and to correlate changes in this cytokine with changes in plasma noradrenaline, plasma renin activity, and weight. DESIGN--A prospective study of the role of TNF alpha in severe chronic heart failure. Blood samples were collected at intervals of three months. SETTING--Medical research centre of a teaching hospital. PATIENTS--16 patients with chronic stable severe heart failure. INTERVENTIONS--Vasodilator treatment with captopril or flosequinan. MAIN OUTCOME MEASURES--Changes in TNF alpha and the correlation with changes in plasma noradrenaline, plasma renin activity, and weight during optimal medical treatment for one year. RESULTS--The mean concentration of TNF alpha was greater than the upper 95% confidence interval for healthy controls throughout the year of the study but there was considerable between and within patient variation. No correlation was seen between TNF alpha and plasma noradrenaline, plasma renin activity, or weight. CONCLUSIONS--The stimulus resulting in enhanced plasma concentrations of TNF alpha in congestive heart failure remains unclear and concentrations at any particular time were not prognostic.

Full text

PDF
141

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. BERKOWITZ D., CROLL M. N., LIKOFF W. Malabsorption as a complication of congestive heart failure. Am J Cardiol. 1963 Jan;11:43–47. doi: 10.1016/0002-9149(63)90029-8. [DOI] [PubMed] [Google Scholar]
  2. Beutler B., Cerami A. Cachectin: more than a tumor necrosis factor. N Engl J Med. 1987 Feb 12;316(7):379–385. doi: 10.1056/NEJM198702123160705. [DOI] [PubMed] [Google Scholar]
  3. Elborn J. S., Norman D., Delamere F. M., Shale D. J. In vitro tumor necrosis factor-alpha secretion by monocytes from patients with cystic fibrosis. Am J Respir Cell Mol Biol. 1992 Feb;6(2):207–211. doi: 10.1165/ajrcmb/6.2.207. [DOI] [PubMed] [Google Scholar]
  4. Levine B., Kalman J., Mayer L., Fillit H. M., Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med. 1990 Jul 26;323(4):236–241. doi: 10.1056/NEJM199007263230405. [DOI] [PubMed] [Google Scholar]
  5. Lähdevirta J., Maury C. P., Teppo A. M., Repo H. Elevated levels of circulating cachectin/tumor necrosis factor in patients with acquired immunodeficiency syndrome. Am J Med. 1988 Sep;85(3):289–291. doi: 10.1016/0002-9343(88)90576-1. [DOI] [PubMed] [Google Scholar]
  6. McMurray J., Abdullah I., Dargie H. J., Shapiro D. Increased concentrations of tumour necrosis factor in "cachectic" patients with severe chronic heart failure. Br Heart J. 1991 Nov;66(5):356–358. doi: 10.1136/hrt.66.5.356. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Michie H. R., Manogue K. R., Spriggs D. R., Revhaug A., O'Dwyer S., Dinarello C. A., Cerami A., Wolff S. M., Wilmore D. W. Detection of circulating tumor necrosis factor after endotoxin administration. N Engl J Med. 1988 Jun 9;318(23):1481–1486. doi: 10.1056/NEJM198806093182301. [DOI] [PubMed] [Google Scholar]
  8. PITTMAN J. G., COHEN P. THE PATHOGENESIS OF CARDIAC CACHEXIA. N Engl J Med. 1964 Aug 20;271:403–CONTD. doi: 10.1056/NEJM196408202710807. [DOI] [PubMed] [Google Scholar]
  9. Resnik H., Friedman B. STUDIES ON THE MECHANISM OF THE INCREASED OXYGEN CONSUMPTION IN PATIENTS WITH CARDIAC DISEASE. J Clin Invest. 1935 Sep;14(5):551–562. doi: 10.1172/JCI100705. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Riley M., Elborn J. S., McKane W. R., Bell N., Stanford C. F., Nicholls D. P. Resting energy expenditure in chronic cardiac failure. Clin Sci (Lond) 1991 Jun;80(6):633–639. doi: 10.1042/cs0800633. [DOI] [PubMed] [Google Scholar]
  11. Starnes H. F., Jr, Warren R. S., Jeevanandam M., Gabrilove J. L., Larchian W., Oettgen H. F., Brennan M. F. Tumor necrosis factor and the acute metabolic response to tissue injury in man. J Clin Invest. 1988 Oct;82(4):1321–1325. doi: 10.1172/JCI113733. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Tracey K. J., Lowry S. F., Fahey T. J., 3rd, Albert J. D., Fong Y., Hesse D., Beutler B., Manogue K. R., Calvano S., Wei H. Cachectin/tumor necrosis factor induces lethal shock and stress hormone responses in the dog. Surg Gynecol Obstet. 1987 May;164(5):415–422. [PubMed] [Google Scholar]
  13. Tracey K. J., Vlassara H., Cerami A. Cachectin/tumour necrosis factor. Lancet. 1989 May 20;1(8647):1122–1126. doi: 10.1016/s0140-6736(89)92394-5. [DOI] [PubMed] [Google Scholar]

Articles from British Heart Journal are provided here courtesy of BMJ Publishing Group

RESOURCES